Liver Diagnostics Articles & Analysis
8 news found
Hepatic steatosis can progress to nonalcoholic steatohepatitis (NASH) with fibrosis, and NASH-associated liver failure is one of the leading causes of liver transplant in the United States. ...
In these cases, transient elastography may have underestimated the skin to capsule distance, indicating that it may have been measuring subcutaneous fat rather than liver tissue due to its shallower and fixed depth of measurement. “Measuring patients with fatty liver disease and high BMI is challenging because the increased thickness of subcutaneous ...
With 100 million Americans affected by fatty liver disease, one-fifth will progress to a more severe form of the condition and are at further risk of developing cirrhosis and liver cancer. ...
If you’re ready to transform your liver practice, we’re ready to show you how. Discover how fast, accurate and easy VelacurTM is to assess liver health at the inaugural Liver Connect conference, April 16-17, 2021, hosted by the Chronic Liver Disease Foundation. Visit our in-person booth for live demos of Velacur, the ...
In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and increase survival for the growing population ...
Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and ...
Together these patents will extend protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. ...
Glycotest Inc., announced today that a Japanese patent has been granted that provides important protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and ...